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Abstract
Introduction: Charcot–Marie–Tooth neuropathy (CMT) is a genetically hetero-
geneous group of peripheral neuropathies. In addition to the classical clinical
phenotype, additional features can occur. Methods: We studied a wide range of
additional features in a cohort of 49 genetically confirmed CMT patients and
performed a systematic literature revision. Results: Patients harbored a PMP22
gene alteration (n = 28) or a mutation in MPZ (n = 11), GJB1 (n = 4), LITAF
(n = 2), MFN2 (n = 2), INF2 (n = 1), NEFL (n = 1). We identified four novel
mutations (3 MPZ, 1 GJB1). A total of 88% presented at least one additional
feature. In MPZ patients, we detected hypertrophic nerve roots in 3/4 cases that
underwent spinal MRI, and pupillary abnormalities in 27%. In our cohort, rest-
less legs syndrome (RLS) was present in 18%. We describe for the first time
RLS associated with LITAF or MFN2 and predominant upper limb involvement
with LITAF. Cold-induced hand cramps occurred in 10% (PMP22, MPZ,
MFN2), and autonomous nervous system involvement in 18% (PMP22, MPZ,
LITAF, MFN2). RLS and respiratory insufficiency were mostly associated with
severe neuropathy, and pupillary abnormalities with mild to moderate neuropa-
thy. Conclusions: In CMT patients, additional features occur frequently. Some
of them might be helpful in orienting genetic diagnosis. Our data broaden the
clinical spectrum and genotype–phenotype associations with CMT.
Introduction
Charcot–Marie–Tooth (CMT) neuropathy (also called
hereditary motor and sensory neuropathy or HMSN) is a
rare disorder with a prevalence of one in 2500 (Skre
1974). CMT is clinically characterized by muscle wasting
and weakness in the distal limbs resulting in steppage gait
as well as distal sensory loss. Foot deformities such as pes
cavus and hammer toes are frequently present (Rossor
et al. 2013; Timmerman et al. 2014). Usually, the disease
course is slowly progressive and in some cases, the use of
a walker or wheelchair is necessary later in life (Timmer-
man et al. 2014). Besides the classical clinical appearance
of CMT patients, additional symptoms have been
described in association with mutations in certain genes,
such as pupil abnormalities with mutations in the myelin
protein zero (MPZ) gene (De Jonghe et al. 1999; Hattori
et al. 2003; Stojkovic et al. 2003), hearing impairment in
association with pathogenic variants in the gap junction
protein beta 1 (GJB1) gene (Hattori et al. 2003), or focal
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segmental glomerular sclerosis (FSGS) with mutations in
the inverted formin 2 (INF2) gene (Boyer et al. 2011;
Mademan et al. 2013).
CMT has been subdivided into three forms by nerve
conduction velocity (NCV) studies: a demyelinating form
with motor NCV in the upper limbs below 38 m/sec
(CMT1), an axonal form with NCV above 38 m/sec
(CMT2) (Harding and Thomas 1980), and an intermedi-
ate form with NCV between 25 and 45 m/sec (Davis et al.
1978). The neuropathological hallmark of CMT1 is seg-
mental de- and remyelination and onion bulb formations.
In CMT2 patients, nerve biopsies typically show axonal
loss and regenerative sprouting (Schr€oder 2001). Both
histopathological abnormalities are present in intermedi-
ate CMT. At the molecular genetic level, CMT is very
heterogeneous with mutations in over 80 causative genes
known so far and all possible modes of inheritance
(Azzedine et al. 2012; Timmerman et al. 2014). The most
frequently mutated gene is peripheral myelin protein 22
(PMP22), leading to CMT1A (duplication or point muta-
tion) or hereditary neuropathy with liability to pressure
palsies (HNPP, deletion or point mutation) (van Paassen
et al. 2014). Novel parallel gene sequencing techniques
[next-generation sequencing (NGS), whole-exome
sequencing (WES)] are nowadays available (Rossor et al.
2013); however, the costs for WES in a diagnostic setting
are still high and not (yet) covered by health insurances
in many countries. Furthermore, the novel genetic tech-
niques usually lead to a large number of variants of which
the causative relation with the disease is often unclear.
Here, we studied the occurrence of additional features
in a large cohort of genetically defined CMT patients and
performed a systematic revision of the literature. We
explored whether the presence of diverse associated clini-
cal features, such as hypertrophic nerve roots or pupil
abnormalities, might contribute to identify the causative
gene in CMT patients. We also examined whether the
occurrence of additional features correlated with the
CMTNS2 neuropathy severity score.
Patients and Methods
Patient selection
We included 49 patients with genetically confirmed CMT
or HNPP that were followed in our neuromuscular out-
patient clinic (Department of Neurology, University
Hospital RWTH Aachen, Germany) from January 2010 to
December 2014 (Table 1). In addition, we searched the
database of the Department of Nephrology (University
Hospital RWTH Aachen, Germany) for patients born
after 1970 presenting focal segmental glomerular sclerosis
(FSGS) diagnosed on kidney biopsy. We identified 20
FSGS patients and screened them for an additional
polyneuropathy, using a questionnaire on neuropathy
symptoms and a clinical neurological examination. The
study was approved by the ethical committee of the
RWTH University Aachen, Germany.
Clinical and paraclinical examinations
In all patients, we performed a detailed history taking,
and general clinical and neurological examination with
particular attention for additional features (Table 2). The
feature cold-induced hand cramps was asked for
anamnestically and the presence of scoliosis was derived
from the patients’ medical reports in a retrospective man-
ner. We applied the CMT neuropathy score version 2
(CMTNS2) in 37 patients, in order to evaluate the
severity of neuropathy: mild (range 0–10), moderate
(range 11–20), or severe (>20, maximum 36) (Table 1)
(Murphy et al. 2011). We systematically performed motor
and sensory nerve conduction velocities (NCV) at the
upper limbs in all patients and additionally at the lower
limbs in some. Prior to this study, a lumbar puncture
was performed in two CMT patients (patients 2 and 6), a
magnetic resonance imaging (MRI) of the thoraco-
lumbo-sacral spine (Philips Intera, 1.5 Tesla, Andover,
MA) in patients 2, 4, 6, 7, and 13, a MRI of the cervical
spine in patient 12 and a MRI of the brain in patients 1,
2, 5, 6, 12, and 22 for diagnostic purposes. Sural nerve
biopsies were obtained previous to the study for diagnos-
tic reasons in patients 1, 2, 6, 23, 24, and 47, after written
informed consent. The biopsies were processed following
standard procedures (Weis et al. 2012). Semithin sections
were stained with toluidine blue and both light and elec-
tron microscopic studies were performed.
Molecular genetic analyses
The molecular genetic tests were performed using genomic
DNA from total peripheral blood samples following stan-
dard procedures, after obtaining patients’ written informed
consent. Sanger sequencing or multiplex ligation-depen-
dent probe amplification (MLPA) combined with
microsatellite marker method was performed in 46 CMT
patients. A molecular genetic analysis of INF2 was con-
ducted in two patients with a polyneuropathy and histolog-
ically proven FSGS (from the initial cohort of 20 patients
with FSGS, see above). NGS-based panel diagnostics for
mutations in 71 CMT-causing genes was done in three
patients (patients 6, 10, and 46; Tables 1 and 2), in whom
previous single-gene analyses had not revealed a causative
mutation. In addition, a segregation analysis was per-
formed in two families (patient 1 with healthy mother and
healthy sister; patients 7, 8, 9 with healthy mother and
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affected father – family 2; Table 1). We used the prediction
programs SIFT (sorting intolerant from tolerant algo-
rithm), PolyPhen2 (polymorphism phenotyping version 2),
and Provean Sift (protein variation effect analyzer) to verify
pathogenicity of the identified variants (Table 1).
Literature search and meta-analysis
In order to study the additional features reported in
CMT patients so far, we conducted a systematic review in
PubMed from 1985 to 2014. We included published CMT
patients in whom a genetic defect was identified, and
excluded patients with other hereditary neuropathies,
such as hereditary motor neuropathies (HMN) or heredi-
tary sensory (and autonomic) neuropathies (HSN,
HSAN). CMT patients with compound heterozygous
mutations in two different genes were also excluded, since
no unequivocal genotype–phenotype correlation could be
made. These criteria led to 280 publications that have
been included in this study (Appendix S1).
Results
Patient cohort
Our study cohort included 49 patients with a genetically
confirmed diagnosis of CMT or HNPP (Table 1). Nine-
teen patients belonged to eight different families and 30
patients were isolated cases. Six distinct mutations have
been identified in the MPZ gene, of which three were
novel (patients 1, 5; and patients 7, 8, 9 belonging to
family 2) and predicted to be pathogenic by the three
prediction programs applied (Table 1). Furthermore, the
variants co-segregated with the disease status in the
healthy mother and sister of patient 1, as well as in the
healthy mother, affected father (patient 8) and brother
(patient 9) of index patient 7. The two patients carrying
the same c.293G>A, p.R98H mutation in MPZ (patients 6
and 10) were not related. Eighteen patients carried a
PMP22 duplication, nine had a PMP22 deletion, and one
harbored a point mutation in the PMP22 gene. In four
patients, a pathogenic variant in the GJB1 gene was iden-
tified, of which the c.303dup, p.E102Rfs*8 mutation in
GJB1 in the related patients 16 and 17 was novel (brother
and sister, family 4, Table 1). Two patients belonging to
the same family (mother and son) carried a mutation in
the lipopolysaccharide-induced tumor necrosis factor-a
factor (LITAF) gene, one in the neurofilament protein
light polypeptide (NEFL) gene, one in INF2, and two in
the mitofusin 2 (MFN2) gene. The patient with INF2
mutation has been described previously (Roos et al.
2015). Neuropathy severity, measured using the CMTNS2
score, was mild in seven patients (range 0–10), moderateTa
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in 13 (range 11–20), and severe in 17 cases (>20). Genetic
data, CMTNS2 scores, and CMT subtype of the patients
are summarized in Table 1.
Associated symptoms and signs
The additional features that were ascertained in our CMT
patient cohort are listed in Table 2. A total of 65% (32/
49) of the patients presented two or more additional
symptoms, 23% (11/49) had one, and 12% (6/49)
expressed no additional features (Table 2).
Hypertrophic cauda equina or nerve roots
MRI of the spine revealed a hypertrophic cauda equina in
three patients with a mutation in MPZ (CMT1B): in a
brother and sister (patients 2 and 4) belonging to family
1 and in a third unrelated patient with a distinct MPZ
mutation (patient 6) (Tables 1 and 2; Fig. 1). The
affected father of patients 2 and 4 (patient 3) was not
available for MRI examination and patient 10, who
harbored the same MPZ mutation as patient 6, could not
undergo the examination due to marked respiratory
insufficiency. We did not find hypertrophic nerve roots
or cauda fascicles in the two patients with a mutation in
LITAF (CMT1C), who underwent a cervical (patient 12)
or lumbar MRI (patient 13). In the other study patients,
a spinal MRI was not performed. Hypertrophy of cranial
nerves was not additionally revealed on brain MRI in
patients 2 and 6, neither in the other patients (patients 1,
5 12, 22) in whom a brain MRI was available (Table 2).
Clinical presentation of the three patients with MPZ
mutation and hypertrophic nerve roots
Patients 2 and 4 (brother and sister) had disease onset in
childhood (patient 2) and at 38 years of age (patient 4)
and patient 6 at 62 years (Table 1). They presented typi-
cal symptoms and signs of CMT. Additional symptoms
were scoliosis, anisocoric, and tonic pupils in patient 2,
bilateral carpal tunnel syndrome (CTS), tonic pupils, and
scoliosis in patient 4, and a sleep apnea syndrome in
(A)
(F) (G) (H)
(I) (J) (K)
(B) (C) (D) (E)
Figure 1. Thoraco-lumbo-sacral MRI and
sural nerve biopsies in three CMT1B
patients with MPZ-mutation and
hypertrophic cauda equina/nerve roots. (A–
C) T2-weighted sagittal sections of the
thoracal, lumbar, and sacral spinal column
in patients 6 (A), 4 (B), and 2 (C),
indicating the thickened nerve roots of the
cauda equina (arrows). This is also shown
for patient 2 at a T1-weighted sagittal
section (D) and a T1-weighted coronal
section (E). Arrow heads show congested
intraspinal vessels. (F–H) T2-weighted axial
sections at the level of the fourth lumbar
vertebral body (L4) of patients 6 (F), 4 (G)
and 2 (H), showing extensive hypertrophic
nerve roots of the cauda equina inside the
spinal column. (I–K) Nerve Biopsy pictures
of patients 6 (I, J) and 2 (K) with (J) being
a magnification of (I). Arrow heads show
onion bulb formations, the arrow points
toward a remaining hypomyelinated nerve
fiber. Notice the extensive loss of the large
myelinated fibers.
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patient 6. Pupils could not be evaluated in patient 6 due
to previous bilateral cataract surgery. Patient 4 com-
plained of lower back pains and patient 6 of occasional
lumbar pain radiating in the legs, which can be explained
by the hypertrophic lumbar nerve roots.
NCVs were within the range of demyelinating CMT
with motor NCV in the upper limbs of 19 m/sec (patient
2), 26 m/sec (patient 4), and 18 m/sec (patient 6). Liquor
analysis in patients 2 and 6 revealed elevated protein
levels (1.45 g/L and 0.46 g/L, respectively, normal value
0.15–0.45 g/L), and was not performed in patient 4.
Spinal MRI in the three patients demonstrated bilaterally
multiple enlarged nerve roots within the spinal column at
the lumbar and sacral level (Fig. 1A–H), leading to con-
gested intraspinal vessels (Fig. 1A–C and E). Sural nerve
biopsies showed a prominent loss of large myelinated
fibers (Fig. 1I–K), as well as Schwann cells forming multi-
ple layers of myelin sheaths around lost fibers leading to
onion bulb formations (Fig. 1J and K).
Our revision of the literature revealed the occurrence of
hypertrophic nerve roots at the cervical and/or lumbar
spine in association with MPZ mutations: c.306delA in two
patients and c.167G>A in another two cases, as well as
PMP22 gene alterations in five cases, of which three
patients with PMP22 duplication, one with a homozygous
PMP22 duplication, and one carrying a PMP22 point
mutation (Appendix S1). In our study, we added two dis-
tinct MPZ mutations associated with this feature (Table 1).
Furthermore, hypertrophy of the cranial nerves has also
been described in two patients with a MPZ mutation and
in another two with a PMP22 gene deletion (Appendix S1).
Restless legs syndrome
Restless legs syndrome (RLS) was present in nine patients
of our cohort (18%), five females and four males, aged
27, 32, 33, 39, 51, 54, 56, 63, and 65 years. They carried a
mutation in the MPZ, GJB1, or MFN2 gene (one patient
each), in LITAF (two patients), or a PMP22 duplication
(two patients) or deletion (two patients). CMT patients
with RLS had CMTNS2 scores ranging from mainly sev-
ere (patient 1, 40, 45, 13), to moderate (patient 17) or
mild neuropathy (patient 12) (Table 1).
In the literature, RLS has been associated with three
different CMT genes (Appendix S1), among them also
the genes that we have identified in our patient group,
except for the LITAF and MFN2 genes that were novel
findings in our study.
Respiratory insufficiency and scoliosis
In patient 10 with CMT2-I/J caused by a MPZ mutation,
a severe restrictive respiratory insufficiency with vital
capacity of 1.2 L (36.8% of the theoretical value) leading
to severe dyspnea and orthopnea was diagnosed at the
age of 48 years. Respiratory symptoms started at least
6 years before. Neurological examination at 48 years
revealed distally pronounced weakness and sensory loss,
pes cavus, clawed hands, and fasciculations at the extrem-
ities. She reported onset of CMT symptoms between 20
and 25 years of age. Due to pronounced orthopnea, the
patient was not able to lie down, slept in sitting position,
and needed a CPAP mask for sufficient oxygenation.
Interestingly, patient 6 with the same R98H mutation in
MPZ showed no signs of respiratory compromise
(Table 2). Furthermore, we diagnosed respiratory insuffi-
ciency with a vital capacity of 1.91 L (54% of the theoret-
ical value) at 25 years of age in patient 30 harboring a
PMP22 duplication. CMTNS2 scores were severe in both
patients (Table 1). They did not have a scoliosis as a
possible cause of respiratory problems.
Mild scoliosis was noted in 14 patients and in one
patient (patient 41, CMT1A), scoliosis was severe, necessi-
tating a surgical correction. Three had a mutation in
MPZ (CMT1B), eight had a PMP22 duplication, one a
PMP22 point mutation, one a PMP22 deletion, one car-
ried a GJB1 mutation, and one patient had a mutation in
LITAF (Table 2).
Literature findings revealed that respiratory insuffi-
ciency and scoliosis are frequent additional features in
many different CMT subtypes including those that we
have detected (Appendix S1).
Pupillary abnormalities
Pupillary abnormalities were noticed in three of our
patients with a MPZ mutation. Two of them had the
CMT1B phenotype (patients 2 and 4) and showed tonic
pupils and/or anisocoria. The third patient, with CMT2 I/
J (patient 5), presented tonic pupils, anisocoria, and
mydriasis (Table 2). In patients 3 and 6, reactions to light
were not measurable because of a previous bilateral catar-
act surgery. CMTNS2 scores in our patients with pupil-
lary abnormalities were in the range of mild (patients 4
and 5) or moderate (patient 2) neuropathy severity
(Table 1).
Our literature review revealed that pupillary abnormali-
ties have been reported with mutations in 10 different
CMT-causing genes (Appendix S1). Most frequently
occurring abnormalities are tonic pupils [PMP22, MPZ,
GJB1, SH3 domain, and tetratricopeptide repeat domain
2 (SH3TC2) gene, set-binding factor 1 (SBF1) gene], or
an impaired pupillary reaction [transient receptor poten-
tial cation channel subfamily V, member 4 (TRPV4) gene,
NMYC downstream-regulated gene 1 (NDRG1) gene].
Furthermore, anisocoria [PMP22, MPZ, MFN2, SH3TC2;
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FYVE, RhoGEF, and PH domain-containing protein 4
(FGD4) gene], miosis (PMP22, MPZ) and mydriasis
(MPZ) have been described previously.
Cold-induced hand cramps
In our cohort, cold-induced hand cramps were indicated
during history taking by one patient with MPZ mutation
(CMT1B, patient 7), two cases with PMP22 duplication
(patients 39, 40), one patient with PMP22 deletion
(patient 24), and one with a mutation in MFN2 (patient
48) (Table 2).
In contrast to our findings, literature data revealed this
symptom only in association with a mutation in the
glycyl-tRNA synthetase (GARS) gene (Appendix S1).
Focal segmental glomerular sclerosis
In one of the two patients with histologically proven
FSGS and a polyneuropathy, we identified a pathogenic
mutation in the INF2 gene (patient 47). Literature find-
ings confirmed that renal problems and FSGS in particu-
lar in CMT patients occur so far exclusively in association
with mutations in INF2. In addition, deafness, cerebral
white matter hyperintensities, and enlarged ventricles have
been described in association with INF2 mutations
(Appendix S1). These features were, however, not present
in our patient.
Summary of associated features in CMT
Considering our study cohort and literature data, we
detected more than 80 different additional symptoms or
signs associated with CMT (Appendix S1, Table 3).
Table 3 summarizes the new findings in our cohort com-
pared to the literature (Table 3).
Regarding the additional features of all CMT-causing
genes described in the literature, many additional features
were reported in association with many distinct
CMT-causing genes, for example, vocal cord involvement,
tremor, scoliosis, hand deformities (claw hands and/or
finger contractures), deafness, cognitive impairment,
bulbar symptoms, fasciculations, facial weakness, early
proximal weakness, pain, paresthesias, early onset CMT,
pupillary abnormality, ophthalmoparesis, respiratory fail-
ure/distress, SAS, dysmorphic features, central nervous
system/cranial nerve involvement, brain imaging abnor-
mality, white matter involvement, severe slow NCV, and
kyphosis/lordosis (Table 3, Appendix S1).
On the contrary, other additional symptoms were
described in a single patient or family only and in associ-
ation with only one gene, such as optic neuritis, chronic
vomiting, bowel dysfunction, mutilating arthropathy,
nocturnal vomiting, hyperkeratosis, myokymia, cardiac
insufficiency and cardiomyopathy, involuntary move-
ments, edema, self-abusive behavior, acrocyanosis, lactic
acidosis under fasting conditions, and slowed emptying of
stomach (Appendix S1).
Link between additional features and gene
function?
We studied whether the occurrence of certain additional
symptoms might be related to mutations in genes that
express a similar function. We considered as distinct
functional groups (Azzedine et al. 2012; Timmerman
et al. 2013): genes expressing a role in myelination, mito-
chondrial functioning, cytoskeletal stability and motor
proteins, RNA and protein metabolism, protein folding,
membrane traffic, transcription regulation, channel or
transporter and other/unknown (Appendix S1). However,
we did not find a correlation between the additional
features and the function of the causative genes.
Mutations identified in our cohort
compared with the same mutations
reported in the literature
We compared the clinical phenotype and in particular the
associated features related to the mutations identified in
our cohort with literature findings on the same mutations
(Appendix S2). If clinical data were not available in
addition to the mutation in the literature, the respective
publication was not included in the Appendix S2.
Discussion
We showed that the majority of CMT patients presented
one or more feature in addition to the classical CMT phe-
notype. Several additional features revealed by our study,
such as hypertrophic nerve roots and RLS, seem to be
underestimated. Their occurrence broaden the clinical
spectrum and genotype–phenotype associations in CMT.
Methodological issues of our study and
future perspectives
Due to the partly retrospective nature of our study, some
data such as MRI images or nerve biopsies were lacking
in some patients. Furthermore, although our overall
patient cohort was large considering the rarity of the dis-
ease, some of the subgroups, such as CMT1F and
CMT2A2, were small. However, we additionally included
in our study all data of the currently available literature
(in total 280 papers, Table 3, Appendices S1 and S2), in
order to obtain more data and larger subgroups. Our
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results are very interesting, but prospective larger
multicenter studies will be necessary in the future to
confirm our findings.
Hypertrophic nerve roots as additional
finding in patients with CMT
Hypertrophic nerve roots can occur in hereditary disor-
ders (e.g., CMT1, CMT3, neurofibromatosis), infectious
or inflammatory neuropathies, neoplastic nerve disorders,
and diverse acquired diseases such as amyloidosis (Gins-
berg et al. 1995). Hypertrophied nerve roots in CMT have
been reported previously by using pathological, ultrasono-
graphic, and MRI examinations (Andermann et al. 1962;
Symonds and Blackwood 1962; Marchini et al. 2009;
Sugimoto et al. 2013). Thus, the presence of hypertrophic
nerve roots in CMT is not new, and is probably often not
reported since there is rarely a compelling reason to
perform MRI in patients with CMT. So far, two CMT-
causing genes, PMP22 and MPZ, have been related to this
feature (Butefisch et al. 1999; Kleopa et al. 2002; Simonati
et al. 2002; Marchini et al. 2009) (Table 3, Appendix S1).
Also in our cohort, three CMT1B patients with a MPZ
mutation presented a hypertrophic cauda equina. In con-
trast to another case in which the hypertrophic nerve
roots and cauda resulted in a compression with severe
symptoms and improvement by surgery (Kleopa et al.
2002), our patients did not show signs of medullar com-
pression. Interestingly, we observed hypertrophic nerve
roots in two relatives with CMT1B (brother and sister,
family 1) as well as in a third unrelated individual. The
two mutations in the MPZ gene that were associated with
this feature in our study (Table 1), have been
described in the literature before; however, in those cases,
Table 3. Additional symptoms identified in our CMT cohort and occurrence in the literature.
Autonomous: U urgency/incontinence PMP22,MPZ,MFN2,LRSAM1,TRPV4,SBF1
Autonomous: Postural hypotension PMP22,MPZ,LITAF
Autonomous: Hyperhidrosis PMP22,MPZ,MFN2,GDAP1
Bulbar (dysphagia, dysarthria, cranial
nerve involvement of IX/X)
PMP22,MPZ,GJB1,EGR2,MFN2,GDAP1,NEFL,SH3TC2,MTMR2,TFG,NDRG1,IFRD1,TRPV4,SBF1
Cognitive impairment PMP22,MPZ,GJB1,MFN2,INF2,DYNC1H1,NEFL,DNM2,LITAF,SLC12A6,HK1,AIFM1,SBF1
Cold-induced hand cramps PMP22,MPZ,MFN2,GARS
Carpal tunnel syndrome PMP22,MPZ,PRX,LITAF,FIG 4,TRPV4,FBLN5
Deafness PMP22,MPZ,GJB1,PRX,EGR2,MFN2,PDK3,SURF1,INF2,NEFL,AARS,LRSAM1,SH3TC2,TFG,LITAF,SBF2,
NDRG1,IFRD1
TRPV4,AIFM1,PRPS1
Early onset: PMP22,MPZ,GJB1,PRX,EGR2,MFN2,PDK3,GDAP1,INF2,DYNC1H1,NEFL,TRIM2,KARS,SH3TC2,FIG 4,
DNM2,MTMR2
FGD4,NDRG1,TRPV4,SCL12A6,AIFM1
Eye: Pupillary PMP22,MPZ,GJB1,EGR2,MFN2,SH3TC2,FGD4,NDRG1,TRPV4,SBF1
Facial weakness PMP22,MPZ,EGR2,MFN2,GDAP1,NEFL,SH3TC2,FIG 4,DNM2,MTMR2,NDRG1,TRPV4,TRG,SLC12A6,
HK1,SBF1
Fasciculations PMP22,MPZ,PRX,EGR2,NEFL,HINT1,LRSAM1,SH3TC2,RAB7,TFG,HSPB1,AIFM1
Hand deformities PMP22,MPZ,PRX,EGR2,GDAP1,INF2,LMNA,NEFL,SH3TC2,FIG 4,MTMR2,SBF2,NDRG1,HSPB1,HK1,FBLN5
MRI, brain: White matter involvement PMP22,MPZ,GJB1,MFN2,INF2,SH3TC2,NDRG1,SLC12A6,AIFM1
MRI, spinal: Hypertrophic nerve roots PMP22,MPZ
Pain PMP22,MPZ,GJB1,MFN2,GDAP1,INF2,DYNC1H1,MARS,HARS,SH3TC2,RAB7,FIG 4,TFG,LITAF,SBF2,HSPB1
Paresthesia PMP22,MPZ,GJB1,PRX,MFN2,NEFL,FIG 4,DNM2,TFG,LITAF,HSJ1,MED25,FBLN5
Renal problems INF2
Respiratory insufficiency PMP22,MPZ,PRX,EGR2,MFN2,GDAP1,SH3TC2,FIG 4,MTMR2,TFG,TRPV4,FBLN5
Restless legs syndrome PMP22,MPZ,GJB1,MFN2,LITAF
Skeletal: Congenital hip dysplasia PMP22,EGR2
Skeletal: Hyperkyphosis INF2,PRX,MFN2,GDAP1,SLC12A6
Skeletal: Scoliosis PMP22,MPZ,GJB1,PRX,EGR2,MFN2,GDAP1,SURF1,INF2,LMNA,NEFL,GARS,SH3TC2,RAB7,FIG 4,
MTMR2,LITAF,FGD4
SBF2,NDRG1,HSPB8,TRPV4,HK1,FBLN5,SBF1
Skeletal: Ulnar deviation of hands PMP22,INF2
Tremor PMP22,MPZ,GJB1,PRX,EGR2,MFN2,PDK3,INF2,DYNC1H1,NEFL,SH3TC2,FIG 4,TFG,LITAF,FGD4,NDRG1,
IFRD1,TRPV4
SCL12A6,HK1
Upper limb predominant LITAF,GARS
Bold: new findings in current patient cohort; italics and underlined: findings in current study that have been reported previously; not underlined,
not italics and not bold: literature findings. CMT, Charcot–Marie–Tooth neuropathy; U, urinary. Additional features are listed in alphabetical order.
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hypertrophic nerve roots were not reported
(Appendix S2). Hypertrophic nerve roots in CMT1B-
patients were mainly described in isolated cases (Kleopa
et al. 2002; Simonati et al. 2002) and in only one family
comprising a father and his two affected daughters carry-
ing the Val102 fs mutation in MPZ (Marchini et al.
2009). Hypertrophic nerve roots caused by mutations in
MPZ were not only found in association with the CMT1B
phenotype, but also with congenital hypomyelinating neu-
ropathy (CHN) (Simonati et al. 2002) and Dejerine–Sot-
tas neuropathy (DSS) (Kleopa et al. 2002). Most authors
presume that the thickening of nerve roots is due to a
Schwann cell proliferation in the context of consistent de-
and remyelination over the years (Kleopa et al. 2002;
Simonati et al. 2002). This explanation is further
strengthened by the finding that the number of onion
bulb formations in sural nerve biopsies, indicating active
de- and remyelination, correlated with the occurrence of
spinal nerve root enhancement and thickening on
lumbosacral MRI in CMT patients (Cellerini et al. 2000).
RLS as additional symptom in CMT
RLS was present in 18% of our cohort, which was higher
compared to the prevalence of 9.8% in the general popu-
lation above 65 years of age (Rothdach et al. 2000). In
our cohort, five females (19% of all females, aged 32, 51,
54, 56, and 65 years) and four males (18% of all males,
aged 27, 33, 39, and 63 years) were affected. In contrast
to these quite similar numbers, women in the general
population were found to be affected twice as often as
men (13.9% vs. 6.1%) (Rothdach et al. 2000) and also
female CMT patients showed RLS more frequently than
male CMT patients in previous studies (Boentert et al.
2010, 2014). The prevalence of RLS has previously been
shown to be significantly increased in hereditary neu-
ropathies, including CMT1, CMT2, CMTX, and HNPP
(Hattan et al. 2009). Since RLS is frequently associated
with peripheral neuropathy in general, our findings were,
however, to be expected (Hattan et al. 2009). In our
cohort, eight out of nine patients with RLS harbored
demyelinating subtypes with mutations in the MPZ
(n = 1), GJB1 (n = 1), or LITAF gene (n = 2) or a
PMP22 duplication (n = 2) or deletion (n = 2) and one
patient with RLS displayed an axonal neuropathy with
MFN2 gene mutation (Table 2). In the literature, RLS
was described in cohorts consisting of CMT patients with
PMP22 duplication and MPZ or GJB1 gene mutation
(Appendix S1). Female CMT patients were also found to
be more severely affected by RLS than men (Boentert
et al. 2010, 2014). In our cohort, four patients suffering
from RLS had severe (two male and two female, patient
1, 40, 45, 13), one moderate (male, patient 17), and one
mild neuropathy (male, patient 12) (Table 1). One
hypothesis is that axonal atrophy increases axonal
excitability in primary sensory units of leg muscles which
results in creeping sensations (Iannaccone et al. 1995). As
a consequence, this sensory input in the central nervous
system may lead to the oscillatory leg movements typical
for RLS (Iannaccone et al. 1995). This hypothesis links
axonal atrophy with RLS. In CMT patients, axonal dam-
age may occur in axonal subtypes as well as in demyeli-
nating subtypes, where it develops consequently to the
loss of myelin (Boentert et al. 2010). This might explain
how CMT may predispose to RLS.
Pupillary abnormalities as additional
feature in CMT patients
In our cohort, pupillary abnormalities were seen in three
out of 11 patients with a MPZ gene mutation (27%): two
CMT1B patients belonging to one family (patients 2 and
4) and one isolated CMT2-I/J patient (patient 5)
(Tables 1 and 2). Their pupil changes became apparent at
51, 41, and 23 years of age, respectively. In another eight
patients with MPZ gene mutation, one CMT2 and seven
CMT1, we did not detect pupil changes (Tables 1 and 2).
Families and isolated CMT patients have been described
with pupillary abnormalities harboring mutations in 10
different CMT-causing genes, including the MPZ gene
(Table 3, Appendix S1). Certain MPZ mutations were
found to be particularly associated with pupil abnormali-
ties, such as the Thr124Met mutation leading to CMT2-I/
J in most patients. This mutation is associated with a dis-
tinct clinical phenotype including late onset in the fourth
or fifth decade, pupillary abnormalities, shooting pains,
deafness, explicit sensory disturbances, rapid progression,
various autonomic system involvement, and respiratory
insufficiency (De Jonghe et al. 1999; Stojkovic et al.
2003). Patient 5 of our cohort also showed the CMT2-I/J
phenotype with pupillary abnormalities associated with
the novel MPZ mutation Gly123Ala (Table 1). She com-
plained of painful paresthesia in the lower limbs, hands,
and face, compatible with the lancinating pains described
in patients with the Thr124Met mutation. In contrast, her
disease symptoms already began in the third decade,
disease progression was rather slow, and no further asso-
ciated features such as deafness or autonomic system
involvement were present (Table 2).
Conclusions
We conclude that additional features are present in the
majority of CMT patients. In case of rather specific
features, occurring in association with only one (e.g.,
renal problems) or a few different CMT genes (e.g.,
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hypertrophic nerve roots, Table 3), they might be used to
guide genetic diagnosis by performing one or only a few
single-gene analyses. However, many other additional
symptoms, such as hearing impairment or cognitive
involvement, can present in association with a large num-
ber of distinct genes (Table 3, Appendix S1), which ham-
pers a gene search based on the additional features.
Therefore, in these cases, it might diagnostically be more
efficient to directly perform novel genetic techniques
(WES), in which a large number of genes can be tested at
the same time. However, aside from additional clinical
features, the mode of inheritance, NCVs, and pathological
examination of nerve biopsies also remain important
clues to molecular diagnosis in CMT.
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